Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

23.11.2022 - Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children ... Seite 1

Related Keywords

United States ,Joanne Kurtzberg ,Patricia Steinert ,Duke University Medical Center ,Mesoblast Limited Nasdaq ,Marrow Transplant Research ,Drug Administration ,International Blood ,International Blood Marrow ,Department Of Medicine Center ,Key Points ,Biologics License Application ,United States Food ,Jerome Harris ,Distinguished Professor ,Executive Scientific Director ,Medicine Center ,